MedCity and London Advanced Therapies are pleased to announce that Miltenyi Biotec will be sponsoring the Advanced Therapies Network (ATN) for 2019/2020.

Miltenyi Biotec is a global biotechnology company that provides a range of products and services to advance biomedical research and enable cell and gene therapy. Founded in 1989, the company has 17,000 products worldwide and about 2500 patients are treated annually with cell products using Miltenyi Biotec technologies.

The company’s products and services support scientists, clinical researchers, and physicians across basic research, translational research and clinical applications. Its client base is well aligned with the membership of the ATN which brings together cell and gene therapy experts from academia, industry, government organisations, charities and the NHS.

Part of London Advanced Therapies, the ATN aims to foster collaboration across the cell and gene therapy sector through a series of informative and networking events around the commercialisation challenges faced by this fast-growing area.

CEO of MedCity, Sarah Haywood, said: “Together with London Advanced Therapies we are delighted that Miltenyi Biotec will be sponsoring the Advanced Therapies Network. Cell and gene therapy is at an important stage in its development and collaboration between the different players in this field is vital to better define and address the shared challenges.

“Through its products and services, Miltenyi Biotec provides support to a wide range of researchers and practitioners working at different stages of cell therapy making the company an excellent sponsor for the network.”

Matthew Cobb, Clinical Account Director at Miltenyi Biotec Ltd said: “We at Miltenyi are delighted to be part of this highly valuable network which will be of significant benefit long-term for future patients who will in time receive advanced therapies.  The field of advanced therapies is rapidly developing, and there are many new entities who are entering this area for the first time.

“By being part of the Advanced Therapies Network, they can learn examples of what other customers in previously similar situations have done and are continuing to do to fulfil their long-term aims.

We are happy to share our guidance and experience along this journey in helping to provide patients with beneficial therapies to support their well-being.”

More information on how to join the advanced therapies network can be found at www.advancedtxnetwork.co.uk